UK's Hemogenyx Pharma rises on investment from Prevail Partners
18/09/2023 08:26
** Shares of Hemogenyx Pharmaceuticals HEMO.L soar as much
as 50.8% to 2.79p, their highest since Jan 1
** Stock among top pct gainers across London shares
** The biopharmaceutical group, which develops new therapies
and treatments for blood diseases, says investment fund Prevail
Partners LLC to invest in company through a subscription for
11.1 mln ordinary shares at $0.075/share for $830,000
** Co says subscription price represents a premium of about
240% to the co's closing share price on Sept. 14, when agreement
was reached as to the final terms of the investment
** HEMO signs agreement with Prevail InfoWorks Inc for
clinical services and technologies for its upcoming Phase I
study of its anti-FLT3 chimeric antigen receptor-redirected T
cells in subjects with relapsed/refractory acute myeloid
leukemia
** YTD Hemogenyx stock up ~80%, as of last close
(Reporting by Aby Jose Koilparambil in Bengaluru)
((abyjose.koilparambil@thomsonreuters.com))